Orca Bio Announces FDA Review Extension for Orca-T Treatment

Got story updates? Submit your updates here. ›

Orca Bio, a biotechnology company based in Menlo Park, California, has announced that the U.S. Food and Drug Administration (FDA) has extended its review of the Biologics License Application (BLA) for the company's Orca-T cell therapy for the treatment of hematologic malignancies, or blood cancers. The FDA's decision to extend the review period indicates the agency requires additional time to fully evaluate the data and information submitted by Orca Bio.

Why it matters

Orca-T is a novel cell therapy that uses the patient's own modified immune cells to target and eliminate cancer cells. If approved, Orca-T could provide a new treatment option for patients with blood cancers who have limited effective therapies available. The FDA's extension of the review period suggests the agency is conducting a thorough evaluation to ensure the therapy's safety and efficacy before potentially granting approval.

The details

Orca Bio submitted the BLA for Orca-T in late 2025, seeking approval for the treatment of various hematologic malignancies, including leukemia and lymphoma. The FDA initially set a target action date of April 1, 2026, but has now extended the review period to allow for additional time to complete its evaluation. Orca Bio stated it will continue to work closely with the FDA during the extended review process.

• Orca Bio submitted the BLA for Orca-T in late 2025.
• The FDA initially set a target action date of April 1, 2026.
• The FDA has now extended the review period beyond the initial target date.

What’s next

Orca Bio stated it will continue to work closely with the FDA during the extended review process, and the agency will make a decision on the BLA for Orca-T at a later, undetermined date.